Kendall Park, NJ, United States of America

Chiajen Lai

USPTO Granted Patents = 17 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 152(Granted Patents)

Location History:

Kendall Park, NJ (US) (2008 - 2011)
Princeton, NJ (US) (2013 - 2016)
Livermore, CA (US) (2019 - 2023)

Company Filing History:

8 out of 3,681

Bristol-myers Squibb Compnay

patents

5 out of 919

Gilead Sciences, Inc.

Britsol-myers Squibb Company

patents

Years Active: 2008-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202849 - Crystalline forms of tenofovir alafenamide (2025-01-21),

2. 12152037 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2024-11-26),

3. 11613553 - Methods of preparing 1'-cyano nucleosides (2023-03-28),

4. 11440928 - Crystalline forms of tenofovir alafenamide (2022-09-13),

5. 11339168 - Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors (2022-05-24),

6. 10407438 - Crystalline forms of darunavir (2019-09-10),

7. 10287307 - Crystalline forms of tenofovir alafenamide (2019-05-14),

8. 9453039 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2016-09-27),

9. 8501698 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2013-08-06),

10. 7968718 - Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein (2011-06-28),

11. 7932379 - Methods of producing C-aryl glucoside SGLT2 inhibitors (2011-04-26),

12. 7919598 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2011-04-05),

13. 7820820 - Method of preparation of azaindole derivatives (2010-10-26),

14. 7671199 - Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester (2010-03-02),

15. 7601715 - Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein (2009-10-13),

Title: Chiajen Lai: Innovator in Pharmaceutical Chemistry

Introduction

Chiajen Lai is a prominent inventor based in Kendall Park, NJ (US), known for his significant contributions to pharmaceutical chemistry. With a total of 17 patents to his name, he has made remarkable advancements in the field of drug formulation and therapeutic applications.

Latest Patents

Among his latest patents is the invention of novel crystalline forms of tenofovir alafenamide. This invention relates to the pharmaceutical formulations and therapeutic uses of these crystalline forms in treating viral infections. Another notable patent involves the crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor. This patent details the preparation and characterization of solid forms of the compound and its salts or co-crystals, along with methods of use.

Career Highlights

Chiajen Lai has worked with leading companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and Gilead Sciences, Inc. His work has significantly impacted the development of new therapeutic agents and drug delivery systems.

Collaborations

Throughout his career, Chiajen has collaborated with notable professionals in the field, including Prashant P Deshpande and Janak Singh. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Chiajen Lai's contributions to pharmaceutical chemistry through his numerous patents and collaborations highlight his role as a key innovator in the industry. His work continues to influence the development of effective treatments for viral infections and other medical conditions.

This text is generated by artificial intelligence and may not be accurate.